ASH 2018 | Long-term follow-up after SCRI-CAR19v1 in R/R ALL patients who proceeded to transplant
CD19-directed CAR T-cells have demonstrated high responses in CD19+ acute lymphoblastic leukemia (ALL). Here, the long-term follow-up of the pediatric and young adult ALL patients after SCRI-CAR19v1 treatment in the PLAT-02 trial (NCT02028455) is presented, including the leukemia-free survival (LFS) of patients who proceeded to hematopoietic cell transplant (HCT) following remission after the CAR T-cell therapy. Corinne Summers, MD, of Seattle Children’s Research Institute, Seattle, WA, highlights how there was a trend towards improved LFS for patients without a prior history of HCT, and that HCT benefitted patients who attained complete remission but were at increased risk of relapse with short-term B-cell aplasia. This video was recorded at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA.
